How Finerenone Compares to Other Mineralocorticoid Receptor Antagonists
Finerenone|Cas# 1050477-31-0
Finerenone in Diabetic Nephropathy — NephJC
Potassium management with finerenone: Practical aspects - Wanner - 2022 - Endocrinology, Diabetes & Metabolism - Wiley Online Library
A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes - ScienceDirect
Edgar V. Lerma 🇵🇭 on Twitter: "Finerenone dose adjustments in CKD #ISNWCN 🇲🇾 #Nephpearls https://t.co/iwHSOpFVLH" / Twitter
Missouri Society of Health-System Pharmacists - CE: Nonsteroidal Mineralcorticoid Receptor Antagonists in Diabetic Kidney Disease
Non‐steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease - Bramlage - 2016 - European Journal of Heart Failure - Wiley Online Library
Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO‐DKD trial - Filippatos - 2022 - European Journal of
Clinical Overview: Finerenone for Chronic Kidney Disease Associated With Type 2 Diabetes
Finerenone Dose–Exposure–Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria | SpringerLink
Finerenone in Diabetic Nephropathy — NephJC
Finerenone Dose–Exposure–Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria | SpringerLink
Frontiers | Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus
PDF) Finerenone Dose–Exposure–Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes | NEJM
Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes - ScienceDirect
Finerenone: A Non-steroidal Mineralocorticoid Receptor Blocker for Diabetic Kidney Disease: Trends in Endocrinology & Metabolism
Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist | SpringerLink
Missouri Society of Health-System Pharmacists - CE: Nonsteroidal Mineralcorticoid Receptor Antagonists in Diabetic Kidney Disease
Finerenone dosing based on estimated glomerular filtration rate (eGFR)... | Download Scientific Diagram
Finerenone Dose–Exposure–Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria | SpringerLink
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitu
Finerenone - wikidoc
The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury | PLOS ONE
Safety and dosing of KERENDIA® (finerenone) tablets HCP
